Ampulla of Vater is a peculiar anatomical structure, characterized by the crossroad of three distinct epithelia: Intestinal, ductal pancreatic and biliary. Adenocarcinomas arising in this area represent an opportunity to understand the comparative biology of all periampullary malignancies. These neoplasms can exhibit intestinal, pancreaticobiliary or mixed features, whereas the subclassification based on morphology and immunohistochemical features failed in demonstrating a robust prognostic reliability. In the last few years, the molecular landscape of this tumor entity has been uncovered, identifying alterations that may serve as prognostic and predictive biomarkers. In this review, the histological and genetic characteristics of ampullary carcinomas are discussed, taking into account the main clinical and therapeutic implications related to this tumor type as well. Author contributions: Luchini C, Pea A, Scarpa A and Lawlor RT conceived of and designed the study; Pea A, Riva G, Lawlor RT and Luchini C performed the literature review; all authors contributed to the literature analysis and interpretation; Pea A, Scarpa A and Luchini C wrote the manuscript; all authors performed the final editing and gave approval of the manuscript in its present form. 
INTRODUCTION
Ampullary neoplasms represent a wide array of tum ors arising in the ampulla of Vater, the most common of which is represented by ampulla of Vater carcino ma (AVC), although other rare malignancies, such as neuroendocrine tumors, may be encountered in this location [13] . AVC comprises 30% of pancreatico duodenectomies and 20% of all tumorrelated obs tructions of the common bile duct [46] . Data from the surveillance, epidemiology, and end results registries have indicated an increased number of new diagnoses in the last years, with the average age at diagnosis ranging from 60 to 70 years old [68] . The etiology of am pullary carcinoma has not been clearly defined and an association with a noninvasive component displaying the adenomatocarcinoma sequence similar to colorectal carcinoma may be present [9, 10] . The ampulla of Vater region presents very peculiar histological aspects, as it represents a crossroad of three different epithelia: Intestinal, ductal pancre atic and biliary. This kind of structure characterizes this area, with a unique complexity and morphological heterogeneity [1] . From the histological point of view, coupling morphological and immunohistochemical an alyses, AVCs have been subgrouped into intestinal and pancreatobiliary subtypes based on the epitheli um of origin; in case of coexistence of aspects of both subtypes, the mixed category has been introduced for a more precise classification [1, 1114] . However, the former classification has been challenged by lines of evidence showing a significant interobserver variability upon the interpretation of these patterns, and the mixed subtype being the predominant subgroup of AVCs, representing up to 40% of cases [1517] . In addition, po orly differentiated tumors can further confound the histological classification [1] . The prognostic significance of this histological classification has been subjected to investigation with inconsistent results [1518] that will be briefly discussed in this review.
In recent years, much progress has been made in ch aracterizing the molecular alterations underlying AVC tumorigenesis, showing a complex mutational spectrum that supports only in part the distinction in different histological subtypes [14, 17] . Molecular analysis showed alterations in overlapping pathways that may serve as foundation for developing new therapeutic approaches and may improve early prognostication models. In this review, we will discuss the histological and genetic landscape of AVCs and its clinical implications, with a specific focus on the treatment of choice and on the future perspectives related to this important topic.
HISTOPATHOLOGY

Gross appearance and location
According to the gross appearance and location, AVCs can be divided into three different categories: (1) intraampullary neoplasms, characterized by a intra luminal growth pattern, without extension out of the Oddi's sphincter; (2) periampullary neoplasms, with a significant vegetating component on the duodenal surface of the ampulla, usually adenomatous, nonin vasive, and frequently characterized by an ulcerating part corresponding to the invasive component; and (3) mixed neoplasms, which show both intraampullary and vegetating growth [1821] . In all of these cases, the ampullary region has a typical enlarged macroscopic appearance (Figure 1 ).
Histology and immunohistochemistry
In 2010, the World Health Organization revised the criteria for the pathological diagnosis of ampullary carcinoma to include three distinct histopathological subtypes on the basis of morphology and immunohis tochemical characteristics: (1) the intestinaltype AVCs; (2) the pancreatobiliarytype AVCs; and (3) the mixedtype AVCs [1] . The intestinal type is frequently associated with a noninvasive component (duodenal adenoma). Its morphology is characterized by a colorectallike archi tecture, with tubular or cribriform glands and central necrosis ( Figure 2 ) [11, 22] . The invasive component is us ually smaller than in the pancreatobiliary type and less frequently exhibits adverse pathological factors and lymphovascular and perineural invasion [2326] . This AVC subtype usually expresses intestinal immunomarkers, such as caudalrelated homeodomain transcription factor 2 (CDX2), mucin2 (MUC2) and cytokeratin 20 (CK20) [27] . The pancreatobiliary type is morphologically similar to pancreatic ductal adenocarcinoma or to the can cer of the extrapancreatic bile duct. Complex tubular glands composed of atypical cells and associated with a prominent desmoplastic stroma characterized this subtype ( Figure 3 ) [11, 22] . At immunohistochemistry, those cells stain positively for MUC1, MUC5AC and CK7 [27] . A significant proportion of AVCs, ranging between 18% and 40%, presents a hybrid phenotype charac terized by overlapping intestinal and pancreatobiliary features [28, 29] and frequently by a nondistinctive imm unohistochemistry ( Figure 4 ) [28] . These aspects partially explain the high interobserver variability among path ologists in classifying AVCs subtypes [15, 16, 28] . Different immunohistochemical panels have been prognostic reliability of the histological classification, either individually or within immunohistochemical panels, led to the integration of molecular alterations into clinical practice in order to better define AVCs prognosis and treatment.
GENETIC LANDSCAPE
Although AVCs are usually sporadic neoplasms, they can also arise in the context of familial syndromes. Particularly, patients with familiar adenomatous poly posis (FAP) frequently develop duodenal adenomas and have a 100 to 200fold increased risk of developing AVCs [7, 30, 31] . A previous seminal manuscript has indicated that sporadic AVCs differ from those occurring in FAP, according to frequency (17% vs 64%), as well as in the site of APC somatic mutations, suggesting a different molecular pathogenesis for the two conditions [32] . The molecular basis for AVCs initially concentrated on chro suggested to overcome the difficulties in histological classification, also in order to stratify AVCs prognosis (Table 1) [12, 13, 1517] . A 4marker panel including MUC1, CK20, CDX2 and MUC2 has been proposed by Ang et al [12] . This panel has shown improved capacities in de fining intermediate/mixed cases, although its correla tion with clinical outcomes has not been evaluated. Chang et al [13] proposed a 2marker panel, composed of CDX2 and MUC1, showing that the PB phenotype was associated with a poor prognosis. However, more recent studies questioning the accuracy and reproducibility of this method failed in identifying direct or significant prognostic correlations with the immunohistochemical patterns [15, 16] . Notably, alterations in the "gastric" lineage marker MUC5AC have also been associated with poor outcome in AVCs, but further studies are needed to va lidate its prognostic role [15] . The morphological heterogeneity that characteri zes a significant proportion of AVCs and the lack of a WJGO|www.wjgnet.com [12] (MUC1, MUC2, CDX2, CK20)
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Figure 4 Immunohistochemical analysis of an ampullary adenocarcinoma of mixed subtype (original magnification 20 ×). A: Immunohistochemical analysis
of an ampullary adenocarcinoma of mixed subtype, with cytokeratin 20 (CK20); B: Immunohistochemical analysis of an ampullary adenocarcinoma of mixed subtype, with cytokeratin 7 (CK7). This image highlights that, in the same area, some neoplastic glands may be positive not only for CK7 or for CK20, but for both markers even. The coexpression of an intestinal marker, such as CK20, and of a pancreatobiliary marker, such as CK7, supports the classification as mixed subtype.
mosomal alterations, indicating chromosome 5 loss as an early event in AVC carcinogenesis, and chromosome 17p loss as a poor prognostic moderator [33, 34] . Recent advances in sequencing technologies have permitted the indepth characterization of the AVC molecular profile, providing important insights for the comprehension of the biology of this malignancy [14, 16, 17] . Particularly, two different whole exome sequencing analyses for a total of 240 patients have refined the knowledge about the mutational landscape of AVCs [14, 17] . Both studies confirmed the presence of recurrent alterations in wellknown AVCrelated genes, including TP53, KRAS and those belonging to the Wntpathway, such as APC; at the same time, ELF3 has been indicated as a novel AVC driver gene in this kind of tumor [14] . The association between driver mutations and his tological subtypes has been evaluated with conflicting results. The APC gene, an important actor of the Wnt signaling pathway, is frequently mutated in the intesti nal subtype (50%65% of cases), similar to colorectal cancer [35] , while the pancreatobiliary type exhibits a higher prevalence of mutations in the pancreatic driver genes KRAS, TP53 and SMAD4, with similar frequencies to pancreatic cancer [14, 17, 36] . Although histological subtypes show differences in prevalence for some genes (Table 2) , important drivers, including KRAS, TP53 and ELF3, can be found mutated in all histotypes. The lack of a specific genetic signature for the histological types suggests the existence of common biological mechanisms in the development of ampullary carcinoma, highlighting the heterogeneity of AVCs from the morphological to the molecular levels. This further calls for a reconsideration of the utility of the histological classification, since the genetic landscape indicates the lack of a specific distinction corresponding to morphology [16] . Both the recent wholeexome sequencing studies described inactivating mutations in the tumorsup pressor gene ELF3, in respectively 10% and 12% of cases [14, 17] . In particular, Yachida et al [14] demonstrat ed with functional analyses a role of such a gene as an AVC driver. ELF3 encodes an ETSdomain transcription factor that is implicated in the regulation of epithelial differentiation. Using immortalized epithelial cell lines derived from the common bile duct and duodenal mu cosa and knocked down for ELF3 expression, they de monstrated ELF3 to enhance proliferation, motility and invasion, associated with the concomitant upregulation of markers of epithelialtomesenchymal transition, such as vimentin, matrix metalloproteinase1 (MMP1) and MMP9 [14] . However, the exact functional role of ELF3 as well as its potential role as a prognostic biomarker or target for therapy needs to be further investigated.
Interestingly, ERBB2 amplification has been dem onstrated in up 23% of cases [16, 37] . In a recent report, it was observed in 13% of AVCs regardless of histological subtype and was virtually mutually exclusive with do wnstream mutations in KRAS/NRAS/BRAF, that are res ponsible for resistance of therapies targeting ERBB2 [37] . Molecular profiling of AVCs has recently demonstra ted a higher prognostic reliability than the histological subclassification. Indeed, analyzing a cohort of 80 AVCs, Mafficini et al [16] showed that TP53 and KRAS, which were the most frequently mutated genes, were in respecti vely 41% and 35% of cases, were also independent prognostic predictors of survival regardless of histological subtypes. These data underline the importance of the mixed phenotype and the fact that the ampullary region is composed of various epithelia merging to form the complex epithelium of the ampulla. [14, 17] . Current treatment approaches do not distinguish patients based on subtypes [38, 39] , while molecular al terations may select patients that respond to different chemotherapeutic regimens, regardless of a clear his tological differentiation [17] . In particular, clinical testing for Wntsignaling and microsatellite instability (MSI) could be used to subclassify tumors for target thera pies since therapies targeting the Wntpathway are in development and MSIpositive tumors may respond to immunotherapeutic approaches [17] . The detection of molecular alterations typical of latestages may in the future support the choice of radical surgery with lymphadenectomy, rather than more conservative ap proaches. This highlights the importance of genetic analysis and the need of its future integration within the conventional pathology report.
TUMOR STAGING
The staging of AVCs is challenging due to the high complexity of this district and the threedimensional spread pattern of tumors occurring in this region. In the new AJCC Cancer Staging System Manual, 8 th edition [21] , the pathological tumor (pT) stages have been reclassi fied, taking into account the degree of extensions and therefore improving the clinical and prognostic relevance of each pT stage (Table 3 ). In particular, new subsets for pT1, pT2 and pT3 have been introduced according to survival analyses and suggesting further prognostic variability [40] ; the new pT4 stage comprises tumors in volving peripancreatic arteries/axes, harmonizing with the exocrine pancreatic cancer staging system.
Metastatic lymph nodes are present in up to 60% of surgically resected AVCs [4143] , with a higher rate for pancreatobiliary than intestinal type carcinomas (55% vs 18%) [11] . The new staging system categorized the presence of nodal metastases in a threetiered scale: N0 (no metastatic lymph node), N1 (one or two metasta tic lymph nodes) and N2 (three or more metastatic lymph nodes); this subclassification has demonstrated a better predictive value in stratifying the prognosis than WJGO|www.wjgnet.com Pea A et al . Ampullary carcinoma: Molecular and clinical features the previous dichotomous categories N0 (no metastatic lymph node) vs N1 (at least one metastatic lymph node). To reach a reliable value, the gross sampling of the sur gical specimen should include a minimum of 12 lymph nodes [44] . However, since pancreaticoduodenal nodes are the most frequently involved and are usually resected within the specimen (pancreaticoduodenectomy), even if the minimum threshold of 12 is not met, pN0 should still be assigned. Notably, a preferential lymphatic spread from pancreaticoduodenal nodes to lymph nodes around the superior mesenteric artery has been suggested, highlighting the importance of a systemic and radical ly mphadenectomy in this area [45] . The risk for lymph node metastases according to the T stage is clinically relevant since endoscopic am pullectomy has been proposed for early AVCs. Surgical series assessed a 8%45% risk of lymph node me tastases in tumors limited to ampulla of Vater and/or sphincter of Oddi (pT1a and pT1b, respectively, of the new staging system) [42, 4648] . The role of local excisions in surgically fit patients remains, being therefore con troversial due to the relevant risk of lymph node me tastases also in resected early cancers. Another pT related issue regards the extranodal extension of nodal metastases, a histological feature indicating that the metastatic cells have reached the perinodal adipose tissue. In the new staging system, it has been not taken into account, whereas it has been demonstrated as an important prognostic factor in patients with AVC and other solid malignancies [4957] . Other prognostic factors not included in the staging system but with a potential prognostic role are includ ed among the histologic grading and the perineural invasion.
CLINICAL ASPECTS
In the majority of cases, AVCs are present with obs WJGO|www.wjgnet.com Table 2 Frequency of significantly mutated ampulla of Vater carcinoma genes in different histotypes and compared to colorectal and pancreatic adenocarcinoma (adapted from Yachida et al [14] ) Yachida et al [14] Gingras et al [17] Biankin et al [36] Pancreatic carcinoma, % Colorectal Carcinoma (TCGA), % [35] Intestinal type, % Pancreato-biliary type, % Primary tumor (T)
T category T criteria
TX Primary tumor cannot be assessed T0
No evidence of primary tumor Tis Carcinoma in situ T1
Tumor limited to ampulla of Vater or sphincter of Oddi, or tumor invades beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa T1a
Tumor limited to ampulla of Vater or sphincter of Oddi T1b
Tumor invades beyond the sphincter of Oddi (perisphincteric invasion) and/or into the duodenal submucosa T2
Tumor invades into the muscularis propria of the duodenum T3
Tumor directly invades the pancreas (up to 0.5 cm) or tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic or periduodenal tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery T3a
Tumor directly invades pancreas, up to 0.5 cm T3b
Tumor extends more than 0.5 cm into the pancreas, or extends into peripancreatic tissue or duodenal serosa without involvement of the celiac axis or superior mesenteric artery T4
Tumor involves the celiac axis, superior mesenteric artery, and/or common hepatic artery, irrespective of size Regional lymph nodes (N) N category N criteria NX Regional lymph nodes cannot be assessed N0
No regional lymph node metastasis N1
Metastasis to 1 to 3 regional lymph nodes N2 Metastasis in > 3 regional lymph nodes
Pea A et al . Ampullary carcinoma: Molecular and clinical features highgrade dysplasia determined by endoscopic biopsy, an underlying adenocarcinoma on definitive pathology is present in 50%-100% of patients and usually in the context of voluminous intestinallike villous adenomas, usually larger than tubular adenomas, and for which a radical endoscopic ampullectomy may be difficult [66, 73] . However, endoscopic ampullectomy should be con sidered part of the diagnostic process and potentially curative in cases of highgrade dysplasia and clear re section margins at the final pathological evaluation of the specimen. Considering the significant morbidity and mortality associated with pancreatic surgery, endos copic papillectomy has also been suggested for early ampullary carcinoma, in particular for pT1 tumors [46, 48, 68] . However, to date, this indication remains to date con troversial, mainly due to the clinically relevant risk of lymph node metastases and the high rate of positive resection margins, reserving this procedure for patients unfit for surgical resection [74] . Endoscopic ampullectomy is a safe procedure, characterized by a relatively low rate (about 10%) of postprocedural complications, the most common being acute pancreatitis, followed by papillary stenosis, cholangitis and bleeding [7578] . Most of these complications can be prevented by the placement of temporary pancreatic and biliary stents [77, 79, 80] .
Surgery
Surgical ampullectomy has been proposed as an al ternative to pancreaticoduodenectomy for selected patients with ampullary neoplasms [81] . This procedure is characterized by lower morbidity and mortality than major surgery, also allowing for performance of a partial lymphadenectomy (excluding the lymph nodes from the superior mesentery artery). However, its role in the treatment of AVCs is controversial, for the difficulties to obtain a radical resection [47, 71, 82] . Surgical ampullecto my shares the same complications of the endoscopic ampullectomy, with the risk of duodenal dehiscence and intraabdominal collections as well as additional complications [71, 83] . The current acceptable standard of care for rese ctable AVCs remains the pancreaticoduodenectomy, either with conventional or pyloruspreserving appro ach [42, 46, 47, 84] . Surgery for AVCs is characterized by a high resectability rate, with close to 90% of cases underg oing laparotomy [7, 24, 85] , but also by a higher rate of sig nificant complications than pancreatoduodenectomies performed for pancreatic cancer. Such complications include pancreatic fistula, pneumonia, intraabdomin al infection, anastomotic leak, and delayed gastric emptying [86] .
FUTURE PERSPECTIVES
The histological subtypes have revealed major issues on both interobserver reproducibility and its prognostic reliability. Since the ampulla of Vater is the crossroad of three distinct epithelia, the study of the tumors arising 376 tructive jaundice, resulting in a high resectability rate at diagnosis [4, 58, 59] . Other symptoms, although less com mon, are upper gastrointestinal bleeding, pancreatitis and unspecific abdominal pain [6062] . Ampullary tumors can even be incidentally discovered during endoscopic procedures or at crosssectional imaging performed for other reasons. Despite the potentially high resecta bility rate, only up to 40% of patients undergo surgical resection [6] , mostly due to the advanced age of pre sentation and the significant morbidity and mortality associated with pancreatic surgery.
The diagnostic workup usually involves abdominal imaging using ultrasonography, computed tomography and/or magnetic resonance, aiming at excluding other causes of jaundice and at disease staging. Because of the anatomical location and the frequent small size of the tumor, an ampullary mass is often difficult to detect, but indirect signs such as pancreatic and/or bile duct obstruction/dilation can be observed [62, 63] . Endoscopy plays a major role in the differential diagnosis of an altered papilla (either bulging or ulc erated) as well as in the local staging of the disease. Endoscopic biopsies are characterized by high false negative rates for adenocarcinoma, often underes timating the actual pathology [47, 64] , whereas endoscopic ultrasonography (EUS) guidedbiopsies improve the diagnostic accuracy, assessing the correct pathology in almost 90% of the cases [65] . In the local staging of ampullary masses, EUS plays a primary role thanks to its capacities of estimating the depth of tumor infi ltration within the duodenal wall and in predicting the presence of local node metastases [6668] , although their definitive demonstration is reserved for the histological examination.
ENDOSCOPIC VS SURGICAL TREATMENT
Radical resection represents, to date, the only esta blished curative option for AVCs, while an endoscopic papillectomy is indicated for noninvasive tumors. A radical resection with an adequate lymphoadenectomy is usually recommended for invasive tumors, even if very small, due to the nonnegligible risk of lymph node metastasization or of incomplete tumor resection. The correct local staging is essential to guide further trea tment decisions.
Endoscopic papillectomy
Endoscopic papillectomy is the treatment of choice for benign or noninvasive ampullary lesions. When EUS shows a lesion confined within the mucosa, and there are not histological features of invasion or of highgrade dysplasia upon biopsy, endoscopic ampullectomy should be performed [69, 70] . The following histological examina tion of the endoscopic specimen must report the status of the resection margins and consider the potential presence of an invasive component [66, 71, 72] . In the case of WJGO|www.wjgnet.com Pea A et al . Ampullary carcinoma: Molecular and clinical features in such a location represents a unique opportunity to better refine the knowledge about all periampullary cancers. The anatomical features of the ampulla of Vater may explain the histological heterogeneity of AVCs and the importance of also taking into account the mixed entity. Indeed, a significant part of this tumor type does not meet all the criteria for a definitive subclassification as intestinal or pancreaticobiliarytype. On the basis of such considerations, the integration of the molecular data appears as a fundamental step in understanding AVCs' biology, helping in better stratifying the prognosis, and highlighting potential targets for tailored therapy. Future therapeutic research studies should investigate, more indepth, the AVCs histological and molecular features, which may represent the key to resolving intestinalpancreaticobiliary heterogeneity.
